Can you take Linvoseltamab with Panamax?

The acetaminophen in Panamax has a major potential interaction with Alcoholism.

Chronic alcohol abusers may be at increased risk of hepatotoxicity during treatment with acetaminophen (APAP). Severe liver injury, including cases of acute liver failure resulting in liver transplant and death, has been reported in patients using acetaminophen. Therapy with acetaminophen should be administered cautiously, if at all, in patients who consume three or more alcoholic drinks a day. In general, patients should avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure. They should also be advised to seek medical attention if they experience signs and symptoms of liver injury such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice.

The acetaminophen in Panamax has a major potential interaction with Dehydration.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

Linvoseltamab has a moderate potential interaction with Immunodeficiency.

Linvoseltamab can cause serious, life-threatening, or fatal infections. Neutropenia and febrile neutropenia have been reported with use of linvoseltamab. Assess patients for signs and symptoms of preexisting infection before starting therapy. Evaluate immunoglobulin levels and complete blood cell counts at baseline. Monitor for infection during treatment, especially in patients with neutropenia. Administer prophylactic anti-infectives, vaccines, and immunoglobulin according to clinical guidelines.

Linvoseltamab has a moderate potential interaction with Infection.

Linvoseltamab can cause serious, life-threatening, or fatal infections. Neutropenia and febrile neutropenia have been reported with use of linvoseltamab. Assess patients for signs and symptoms of preexisting infection before starting therapy. Evaluate immunoglobulin levels and complete blood cell counts at baseline. Monitor for infection during treatment, especially in patients with neutropenia. Administer prophylactic anti-infectives, vaccines, and immunoglobulin according to clinical guidelines.

The acetaminophen in Panamax has a major potential interaction with Liver Disease.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

Linvoseltamab has a moderate potential interaction with Liver Disease.

The effect of moderate to severe liver dysfunction (total bilirubin greater than 1.5 times the upper limit of normal with any AST) on the pharmacokinetics of linvoseltamab is unknown. Due to the risk of hepatotoxicity with linvoseltamab, monitor liver enzymes and bilirubin at baseline and during treatment as indicated.

The acetaminophen in Panamax has a major potential interaction with Malnourishment.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

Linvoseltamab has a moderate potential interaction with Neutropenia.

Linvoseltamab can cause serious, life-threatening, or fatal infections. Neutropenia and febrile neutropenia have been reported with use of linvoseltamab. Assess patients for signs and symptoms of preexisting infection before starting therapy. Evaluate immunoglobulin levels and complete blood cell counts at baseline. Monitor for infection during treatment, especially in patients with neutropenia. Administer prophylactic anti-infectives, vaccines, and immunoglobulin according to clinical guidelines.

The acetaminophen in Panamax has a moderate potential interaction with Phenylketonuria.

Several oral acetaminophen and acetaminophen-combination products, particularly flavored chewable tablets, contain the artificial sweetener, aspartame (NutraSweet). Aspartame is converted to phenylalanine in the gastrointestinal tract following ingestion. Chewable and effervescent formulations of acetaminophen products may also contain phenylalanine. The aspartame/phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).

Linvoseltamab has a moderate potential interaction with Renal Dysfunction.

The effect of severe renal dysfunction/end-stage renal disease (CrCl 29 mL/min or less) on the pharmacokinetics of linvoseltamab is unknown.